Somewhat Favorable Press Coverage Somewhat Unlikely to Affect T2 Biosystems (NASDAQ:TTOO) Share Price

News headlines about T2 Biosystems (NASDAQ:TTOO) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. T2 Biosystems earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 46.8525346763692 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern’s analysis:

T2 Biosystems stock traded down $0.09 during trading hours on Thursday, hitting $6.80. 237,134 shares of the stock traded hands, compared to its average volume of 329,353. The company has a debt-to-equity ratio of 1.29, a quick ratio of 0.83 and a current ratio of 0.86. The stock has a market cap of $238.45, a price-to-earnings ratio of -3.24 and a beta of 1.20. T2 Biosystems has a one year low of $2.50 and a one year high of $7.26.

Several analysts recently issued reports on the company. ValuEngine raised T2 Biosystems from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 13th. Zacks Investment Research cut T2 Biosystems from a “buy” rating to a “hold” rating in a research note on Friday, March 23rd. HC Wainwright lifted their price objective on T2 Biosystems from $8.00 to $8.50 and gave the company a “buy” rating in a research report on Thursday, March 29th. Finally, Goldman Sachs assumed coverage on T2 Biosystems in a research report on Monday, January 29th. They set a “neutral” rating and a $5.20 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.12.

ILLEGAL ACTIVITY WARNING: This article was posted by BBNS and is owned by of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://baseballnewssource.com/2018/04/06/t2-biosystems-ttoo-earning-somewhat-favorable-media-coverage-report-finds/2029201.html.

T2 Biosystems Company Profile

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Insider Buying and Selling by Quarter for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players
What does legal betting mean for the baseball industry?
What does legal betting mean for the baseball industry?
Dodgers Use Nine Pitchers in Nine-Inning Game
Dodgers Use Nine Pitchers in Nine-Inning Game


Leave a Reply

 
© 2006-2018 BBNS.